**Name of journal: World Journal of Respirology**

**ESPS Manuscript NO: 7017**

**Columns: Prospective Study**

Phase II trial of carboplatin/docetaxel in patients with resected NSCLC

Uramoto H *et al*. CBDCA plus DTX in resected NSCLC

Hidetaka Uramoto, Ryoichi Nakanishi, Akihiko Uchiyama, Masaaki Inoue, Masakazu Sugaya, Teruo Iwata, Noriyuki Ebi, Takeshi Hanagiri, Fumihiro Tanaka

**Hidetaka Uramoto, Takeshi Hanagiri, Fumihiro Tanaka,** Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu807-8555, Japan

**Ryoichi Nakanishi,** Department of thoracic surgery, Shin-Kokura Hospital, Federation of National Public Service Personnel Mutual Aid Associations, Kokurakita-ku, Kitakyushu 803-0816, Japan

**Akihiko Uchiyama,** Department of surgery, Kyushu Kouseinenkin Hospital, Kitakyushu 806-8501, Japan

**Masaaki Inoue,** Department of chest surgery, Shimonoseki City Hospital, Shimonoseki 750-8520, Japan

**Masakazu Sugaya,** Department of chest surgery, Chubu Rosai Hospital, Nagoya 455-0018, Japan

**Teruo Iwata,** Department of Thoracic Surgery, Niigata Rousai Hospital, Niigata 942-0071, Japan

**Noriyuki Ebi,** Department of respiratory medicine, Iizuka Hospital, Iizuka 820-8505, Japan

**Author contributions:** All authors contributed to this work.

**Supported by** JPJS KAKENHI, No. 25462202, and a UOEH Research Grant for Promotion of Occupational Health; Uramoto H, Hanagiri T and Tanaka F has received research grant to belong to institute from Sanofi-Aventis, Inc. Drs. Nakanishi, Uchiyama, Inoue, Sugaya, Iwata

Correspondence to: Hidetaka Uramoto, MD, PhD, Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan. hidetaka@med.uoeh-u.ac.jp

**Telephone:** +81-93-6917442 **Fax:** +81-93-6924004

**Received:** October 31, 2013 **Revised:** February 15, 2014

**Accepted: February 18, 2014**

**Published online:**

**Abstract**

**AIM**: To investigate the development of a safer chemotherapeutic regimen with better compliance, a total of 67 patients were enrolled as a single arm in a two-stage multi-center phase II study.

**METHODS**: The patients received chemotherapy with carboplatin (CBDCA) with an area under the curve (AUC) of 5, and docetaxel (DTX) at 60 mg/m2 tri-weekly for three cycles after surgery. The primary endpoint of this study was compliance, while the secondary endpoints were the adverse events (AE) and recurrence-free survival (RFS).

**RESULTS**: Sixty-one patients were treated in this study arm. The patients were 43 males and 18 females, with a median age of 64.6 years. Fifty-one patients (83.6%) completed all three cycles of therapy. The presence of Grade 3 and 4 neutropenia was noted in 25% and 66% of the patients, respectively. The non-hematological adverse events were less frequently reported, and no treatment-related death was registered. The two-year RFS and OS rates of the 61 patients were 69.8% and 88.3%, respectively.

**CONCLUSION**: A tri-weekly schedule of CBDCA and DTX as adjuvant chemotherapy showed a favorable feasibility.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words:** Non-small cell lung cancer; Adjuvant chemotherapy; Carboplatin; Docetaxel; Treatment compliance; surgical resection.

**Core tip:** Adjuvant chemotherapy with a tri-weekly schedule of carboplatin and docetaxel was feasible in Japanese non-small cell lung cancer patients. In clinical practice, this regimen represents a potential treatment option that may be superior to other regimens. The main limitation associated with this study is the small number of patients enrolled. Therefore, it is important to employ a reference arm for any future randomized clinical trials evaluating this treatment regimen.

Uramoto H, Nakanishi R, Uchiyama A, Inoue M, Sugaya M, Iwata T, Ebi N, Hanagiri T, Tanaka F. Phase II trial of carboplatin/docetaxel in patients with resected NSCLC.

**Available from: URL:**

**DOI:**

**INTRODUCTION**

Lung cancer is one of the deadliest cancers worldwide, with the highest incidence and mortality among all cancers[1]. Many of the patients with NSCLC demonstrate a recurrence of the tumor and die despite undergoing a complete surgical resection[2]. This suggests that occult metastases are often present at the time of surgical intervention[3, 4]. Therefore, adjuvant chemotherapy is needed to improve the prognosis of patients[5]. The benefits of adjuvant chemotherapy have been demonstrated using mainly cisplatin (CDDP)-based chemotherapy[6]. However, many problems still remain. For example, CDDP-containing regimens pose unacceptable toxicity and require hydration to prevent renal toxicity, and also add a risk for lung edema with a reduced vascular bed after a lung resection[7]. As a result, these regimens often have low patient compliance. Furthermore, treatment-related deaths sometimes occur with CDDP chemotherapy, even though it might prevent recurrence when given in an adjuvant setting and most of the population who cannot gain a privilege actually[8,9]. Given the poor compliance, randomized studies have failed to prospectively confirm a statistically significant role for adjuvant chemotherapy for NSCLC patients[10, 11].

On the other hand, CBDCA is more favorable with less toxicity than most of the anticancer drugs for advanced lung cancer. Further, CBDCA was not far behind from CDDP in post-surgical situation[12], though CDDP-based chemotherapy yields a barely significant survival advantage compared with combination chemotherapy consisting of CBDCA plus a second generation agent in patients with advanced NSCLC[13].In fact, there might be large differences between the outcomes of chemotherapy for patients with advanced NSCLC with a large tumor burden and patients receiving the treatment in the adjuvant setting who are at least macroscopically tumor-free. We previously reported that a bi-weekly schedule of CBDCA combined with paclitaxel (PTX) or gemcitabine (GEM) also had acceptable toxicity[7,14]. In fact, CBDCA treatment regimens are available for outpatients for a short duration of treatment. However, the compliance in the previous studies was still unsatisfactory.

Docetaxel (DTX) has pharmacological actions similar to its congener, PTX. However, these drugs have pharmacodynamic and pharmacokinetic differences[15]. In fact, DTX is the only agent currently approved for both first- and second-line treatment of advanced NSCLC[16]. Furthermore, DTX is superior to vinca alkaloid-based regimens, which are the most common treatment used in the adjuvant setting, in terms of the OS and safety for advanced NSCLC patients. DTX-based regimens also improved the patient quality of life (QOL) compared with vinca alkaloid-based regimens in those with advanced NSCLC[17]. Therefore, CBDCA with DTX may offer an acceptable alternative for patients with advanced NSCLC.

The purpose of this study was to test the completion rate as a primary endpoint and the adverse events (AE) and relapse-free survival (RFS) as secondary endpoints in patients with stage IB-IIIA NSCLC receiving tri-weekly CBDCA (AUC 5) and DTX (60 mg/m2) in a two-stage multi-institutional study.

**MATERIALS AND** **METHODS**

### ***Eligibility criteria***

### Patients were eligible for the main trial if they fulfilled the following local criteria for a pathologic diagnosis of stage IB, II or IIIA NSCLC[18] after a curative operation and mediastinal lymphadenectomy: age 20-80 years; Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1; a leukocyte count of 4000 mm3 and a neutrophil count of 2000 mm3 or greater; a hemoglobin level of 9.0 g/dL or greater; a platelet count of 100000 uL or greater; a serum bilirubin level less than 1.5 mg/dL; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels equal to or less than two times the institutional normal and a creatinine concentration less than 1.5 mg/dL. The patients were ineligible if they had a concurrent malignancy, uncontrollable complications, severe postoperative morbidity; previous treatment including chemotherapy, radiotherapy, or immunotherapy; hypersensitivity to therapeutic agents; the possibility of being pregnant and other conditions such as hepatic inflammation, as judged by the attending physician. This study was registered with University Hospital Medical Information Network-Clinical Trials Registry, available at <http://www.umin.ac.jp/ctr/index-j.htm> (ID: UMIN000002425).

### ***Pretreatment and follow-up evaluations***

Before enrollment, all patients underwent a full history and clinical examination which included the performance status, complete blood cell count (CBC), electrolytes, glucose, liver function tests, blood urea and creatinine levels, a urinalysis, ECG and chest X-rays. Additional imaging investigations were performed if clinically indicated or in order to measure areas of known disease. During the study, all patients were monitored for symptoms of toxicity and underwent regular clinical examinations. Hematological assessments and chest X-rays and tumor marker studies were performed at least every three and four weeks, respectively.

***Treatment schedule and trial design***

This was a two-stage multi-institutional prospective study. A dose of 60 mg/m2 DTX and CBDCA area under the curve (AUC) of 5 were given intravenously on days 1 and every three weeks for a maximum of three cycles[19]. The treatment was started within 10 wk of surgery. Calvert’s formula was used to calculate the AUC for CBDCA[20], whereas the creatinine clearance was determined using the Jellifie formula[21]. A short premedication with 20 mg of dexamethasone and a 5-HT3 receptor antagonist was administered intravenously 30 min before the patients received the rest of the DTX. CBDCA and DTX were dissolved in physiological saline or 5% glucose to a volume of 250 mL, and were administered by intravenous drip infusion in 90 min.

Complete blood cell counts were measured before the beginning of each new treatment course. Treatment was delayed one week if the leukocyte count was less than 3000 (/µL), the neutrophil count was less than 1500 (/µL) or the platelet count was less than 75000 (/µL). The patient was withdrawn from the study if these conditions were not resolved within six weeks[22]. The dose of DTX was reduced to 50 mg/m2 and the dose of CBDCA was reduced to AUC 4 only once through a full course when the neutrophil count was 1000 (/µL) or less, or the platelet count was 25000 µL or less with previous treatment, or if grade 3 non-hematological toxicities occurred. The maximum grade on the National Cancer Institute of Common Toxicity Criteria for Adverse Events (Version 3.0) was reported for both the hematological and non-hematological toxic effects. The highest toxicity grade for each patient in all cycles of chemotherapy was used for toxicity analysis. Patients did not receive prophylactic granulocyte colony-stimulating factor (G-CSF) during any cycle. The criteria for removal from the treatment arm were intolerable toxicity or withdrawal of consent. The choice of any subsequent treatment depended on the institution. The Institutional Review Board approved this study and informed consent was obtained from either the patients or their legal guardians.

***Observations and evaluations***

The primary endpoint of this study was compliance with the chemotherapy protocol, while the secondary endpoints were the AE and RFS. All eligible patients who received any treatment were considered assessable for toxicity. The blood chemistry studies and evaluations of the serum levels of tumor markers were repeated every cycle. The follow-up period after accrual closure was planned to be 24 mo.

***Statistical analysis***

The expected and threshold values of the treatment completion rate were 80% and 65%, respectively[7,14].The number of patients required was determined with an risk of 0.05 and  risk of 0.2. Simon’s optimal design[23] was applied to recruit the patients and the number of patients required was calculated to be 65 patients by considering the likely number of cases with incomplete treatment. If completion of treatment was observed in < 21 patients among the first 31 patients, this study was to be terminated; if it was observed to be ≥ 22 patients, recruitment would be allowed. The events considered in the RFS were locoregional and distant recurrence. The RFS was calculated from the date of registration to the date of recurrence. The overall survival (OS) was calculated from the date of enrollment to the date of death or last known contact. The terminal event of the overall survival analysis was death attributableto cancer or non-cancer causes. The Kaplan-Meier method was used to estimate the probability of survival, and survival differences were analyzed by the log-rank test. The difference was considered to be significant for values of *P <* 0.05. The data were analyzed using the Stat View software program (Abacus Concepts, Inc., Berkeley, California, United States).

**RESULTS**

*Patient characteristics*

Sixty-seven patients were enrolled in this multi-institutional trial from September 2009 to August 2011. Thirty-one patients were evaluated at the interim analysis. Completion of treatment was observed in 23 patients among the first 31 patients at the interim analysis[24]. Six of the 67 patients enrolled were excluded from the final analysis; three due to ineligibility criteria and three patients due to not receiving the study treatment. A total of 61 patients were therefore evaluable, and their characteristics are shown in Table 1. The 61 patients included 43 males and 18 females, with a median age of 64.6 years (range, 42-79 years). The tumors included 45 adenocarcinomas, 13 squamous cell carcinomas, two pleomorphic carcinomas and one giant cell carcinoma. Nineteen patients were in stage IB, 11 in IIA, 10 in IIB and 21 in IIIA. None of the patients received either induction or postoperative radiotherapy.

***Compliance with chemotherapy***

The regimen was judged to be safe and tolerable in the first stage, and therefore, patients were accrued as planned[24].Fifty-one patients completed all cycles of therapy, and therefore, the completion rate was 83.6% (Table 2). The median number of treatment cycles for all patients was three. The primary reason for premature discontinuation was hematological toxicity (*n* = 6). The four patients did not complete all cycles because of a pulmonary fistula in two cases, diarrhea in one case and an intra-abdominal abscess from ileocecal diverticulitis in one case. The transition rate to outpatient status in all cycles was 49.2%. As a consequence of a dose reduction, the mean and median dose intensity of carboplatin were 4.3 (86.7%) and 4.3 (86.7%) AUC, and those of DTX were 51.8 mg/m2 (86.3%) and 53.3 mg/m2 (88.8%), respectively.

***Safety***

The toxicity profiles are summarized in Table 3. Grade 3 and 4 neutropenia were observed in 25% and 66% of patients, respectively. Grade three febrile neutropenia developed in 7% of patients, while no grade 4 febrile neutropenia was observed.Severe non-hematological AE were infrequent, and no treatment-related death was registered. Peripheral neuropathy (Grade 1) was observed in four (6.6%) out of the 61 patients.

***Efficacy***

There were 20 events (12: alive with recurrence, 7: dead with recurrence, 1: dead without cancer) recorded in the 61 patients. The overall median follow-up period for all patients was 29.9 mo. The two-year RFS and OS rates of the 61 patients were 69.8% and 88.3%, respectively. The two-year RFS rate of the patients with stage IB, II and IIIA tumors was 94.1, 69.6 and 50.0%, respectively (*P <* 0.01) (Figure 1B). The two-year OS rate in patients with stage IB, II and IIIA tumors was 94.1, 81.0 and 85.6%, respectively (*P* = 0.0282) (Figure 2B). There was a significant relationship between the pathological stage and the number of recurrences (stage IB-II: 17.9%, IIIA: 59.1%, *P <* 0.01; Table 4).

**DISCUSSION**

The medicinal value of an agent increases when an adequate amount of anticancer drug is given. In fact, an average relative dose intensity less than the median predicted a poor prognosis in diffuse large cell lymphoma[25], and in the patients who received at least 85 percent of the planned dose, the rate of RFS was longer than the group that received less than the optimal dose in breast cancer patients[26]. Furthermore, Neymark *et al*27] reported that the patients' adherence to protocol therapy was linked to a favorable survival in NSCLC.

 Of interest, studies addressing the role of preoperative chemotherapy have found chemotherapy compliance to be more favorable in the preoperative setting than for adjuvant treatment. In fact, the compliance/median DFS for the preoperative and postoperative groups were 93%/32 and 65%/24 mo[28]. However, the successful delivery of CDDP-based chemotherapy in postoperative patents has been difficult, as described above. At present, the compliance has been unsatisfactory, with rates of 56%-74%, except for CALGB 9633[11, 29-31]. Our results showed 83.6% compliance. Recently, Kometani et al[32] reported 93% compliance in patients treated in the CDDP+DTX arm completed 3 planned cycles of chemotherapy. Yang *et al*[33] also reported 85% compliance in patients treated with CBDCA (AUC 5) and DTX (75 mg/m2), which was consistent with our data.

The presence of severe toxicities, specifically neutropenia, was relatively high in our study. The incidence of grade 3/4 neutropenia and grade 3/4 febrile neutropenia was reported to be 86% and 10% for CDDP with DTX for the Japanese patients with completely resected NSCLC, respectively[32].The frequency of grade 3/4 neutropenia in Japanese patients is much higher than that in Caucasian patients treated with the same tri-weekly schedule[31, 34]. The difference in the complication rates might depend on ethnic differences in the population-related pharmacogenomics[35]. Of note, the frequency of severe neutropenia also varies among Japanese and Chinese patients[33]. Therefore, the optimal doses in this combination, and the appropriate application of G-CSF, should also be considered in a future study. Although the treatment was associated with higher toxicity, it was also associated with good compliance, and our results using DTX-based regimens therefore show that they represent new a therapeutic option[32, 36].

The two-year RFS and OS rates of the 61 patients were 69.8% and 88.3%, respectively, in our study. These data were superior to the data in the Japanese lung cancer registry study of 11663 surgical cases, although the data regarding survival are still preliminary and must be followed up[37]. Furthermore, the non-hematological adverse effects were less frequent and no treatment-related death was registered in this trial. However, patients with advanced stage NSCLC had a significantly poorer prognosis in terms of the RFS, although there were no statistically significant differences between stage IB-II and III patients in terms of the OS. Therefore, the selection of regimens with sufficient efficacy for restricting the growth of a recurrence might be needed. Recently, a Japan Intergroup Trial phase III trial of Pemetrexed (PEM) as adjuvant chemotherapy for completely resected non-squamous cell carcinoma has been launched. In the present study, we demonstrated the feasibility of DTX combined with CBDCA; therefore, the next step would be to compare this regimen to CDDP with new drug(s) in a phase III trial.

In a conclusion,adjuvant chemotherapy with a tri-weekly schedule of CBDCA and DTX was feasible in Japanese NSCLC patients. In clinical practice, this regimen represents a potential treatment option that may be superior to other regimens. The main limitation of this study is the small number of patients enrolled, and therefore, it is important to employ a reference arm for any upcoming randomized clinical trials evaluating this treatment regimen.

**ACKNOWLEDGEMENTS**

We are grateful to Professor Kouhei Akazawa(Department of Medical Informatics and Statistics, Niigata University Graduate School of Medicine, Japan), for his statistical advice during the preparation of the article. We also wish to thank Sumi Nakamura, Miyu Yamamato, and Ayano Tadano for their valuable technical assistance.

**COMMENTS**

***Background***

The benefits of adjuvant chemotherapy have been demonstrated for patients with non-small cell lung cancer (NSCLC). However, some problems still remain, and treatment-related deaths sometimes occur. Therefore, the development of a safer regimen with better compliance is still necessary.

***Innovations and breakthroughs***

The present results suggest that adjuvant chemotherapy with a tri-weekly schedule of carboplatin and docetaxel is feasible in Japanese NSCLC patients.

***Applications***

In clinical practice, this regimen represents a potential treatment option that may be superior to other regimens.

***Peer review***

This is a informative and very well-written manuscript, which can be useful for interested readers and investigators of lung cancer.

**REFERENCES**

1 **Subramaniam S**, Thakur RK, Yadav VK, Nanda R, Chowdhury S, Agrawal A. Lung cancer biomarkers: State of the art. *J Carcinog* 2013; **12**: 3 [PMID: 23599685 DOI: 10.4103/1477-3163.107958]

2 **Uramoto H**, Tanaka F. Prediction of recurrence after complete resection in patients with NSCLC. *Anticancer Res* 2012; **32**: 3953-3960 [PMID: 22993343]

3 **Yamashita T**, Uramoto H, Onitsuka T, Ono K, Baba T, So T, So T, Takenoyama M, Hanagiri T, Oyama T, Yasumoto K. Association between lymphangiogenesis-/micrometastasis- and adhesion-related molecules in resected stage I NSCLC. *Lung Cancer* 2010; **70**: 320-328 [PMID: 20363046 DOI: 10.1016/j.lungcan.2010.02.013]

4 **Shimokawa H**, Uramoto H, Onitsuka T, Iwata T, Nakagawa M, Ono K, Hanagiri T. TS expression predicts postoperative recurrence in adenocarcinoma of the lung. *Lung Cancer* 2011; **72**: 360-364 [PMID: 20970877 DOI: 10.1016/j.lungcan.2010.08.024]

5 **Pignon JP**, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell R, Seymour L, Spiro SG, Rolland E, Fossati R, Aubert D, Ding K, Waller D, Le Chevalier T. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. *J Clin Oncol* 2008; **26**: 3552-3559 [PMID: 18506026 DOI: 10.1200/JCO.2007.13.9030]

6 **Winton T**, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, Fry W, Bethune D, Ayoub J, Ding K, Seymour L, Graham B, Tsao MS, Gandara D, Kesler K, Demmy T, Shepherd F. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. *N Engl J Med* 2005; **352**: 2589-2597 [PMID: 15972865 DOI: 10.1056/NEJMoa043623]

7 **Uramoto H**, Nakanishi R, Nagashima A, Uchiyama A, Inoue M, Osaki T, Yoshimatsu T, Sakata H, Nakanishi K, Yasumoto K. A randomized phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer. *Anticancer Res* 2010; **30**: 4695-4699 [PMID: 21115926]

8 **Weiss J**, Eaby B, Stevenson J, Kucharczuk J, Cooper J, Kaiser L, Shrager J, Rengan R, Langer C, Evans T. Adjuvant cisplatin and docetaxel for non-small cell lung cancer: the Hospital of the University of Pennsylvania experience. *J Thorac Oncol* 2010; **5**: 667-672 [PMID: 20234321 DOI: 10.1097/JTO.0b013e3181d409f9]

9 **Douillard JY**, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, Grodzki T, Pereira JR, Le Groumellec A, Lorusso V, Clary C, Torres AJ, Dahabreh J, Souquet PJ, Astudillo J, Fournel P, Artal-Cortes A, Jassem J, Koubkova L, His P, Riggi M, Hurteloup P. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. *Lancet Oncol* 2006; **7**: 719-727 [PMID: 16945766 DOI: 10.1016/S1470-2045(06)70804-X]

10 **Scagliotti GV**, Fossati R, Torri V, Crinò L, Giaccone G, Silvano G, Martelli M, Clerici M, Cognetti F, Tonato M. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. *J Natl Cancer Inst* 2003; **95**: 1453-1461 [PMID: 14519751 DOI: 10.1093/jnci/djg059]

11 **Douillard JY**, Laporte S, Fossella F, Georgoulias V, Pujol JL, Kubota K, Monnier A, Kudoh S, Rubio JE, Cucherat M. Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. *J Thorac Oncol* 2007; **2**: 939-946 [PMID: 17909357 DOI: 10.1097/JTO.0b013e318153fa2b]

12 **Gu F**, Wisnivesky JP, Mhango G, Strauss GM. Carboplatin versus cisplatin-based adjuvant chemotherapy in elderly patients with stages IB, II, and IIIA non-small cell lung cancer in the community setting. *J Clin Oncol* 2013; **31**: 7533.

13 **Hotta K**, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. *J Clin Oncol* 2004; **22**: 3852-3859 [PMID: 15326195 DOI: 10.1200/JCO.2004.02.109]

14 **Sugaya M**, Uramoto H, Uchiyama A, Nagashima A, Nakanishi R, Sakata H, Nakanishi K, Hanagiri T, Yasumoto K. Phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel in patients with completely resected non-small cell lung cancer. *Anticancer Res* 2010; **30**: 3039-3044 [PMID: 20683052]

15 **Lavelle F**, Bissery MC, Combeau C, Riou JF, Vrignaud P, André S. Preclinical evaluation of docetaxel (Taxotere). *Semin Oncol* 1995; **22**: 3-16 [PMID: 7740328]

16 **Belani CP**. Optimizing chemotherapy for advanced non-small cell lung cancer: focus on docetaxel. *Lung Cancer* 2005; **50S2**: S3-S8 [PMID: 16551520]

17 **Fossella F**, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. *J Clin Oncol* 2003; **21**: 3016-3024 [PMID: 12837811 DOI: 10.1200/JCO.2003.12.046]

18 **Mountain CF**. Revisions in the International System for Staging Lung Cancer. *Chest* 1997; **111**: 1710-1717 [PMID: 9187198 DOI: 10.1378/chest.111.6.1710]

19 **Yoshimura N**, Kudoh S, Kimura T, Mitsuoka S, Kyoh S, Tochino Y, Asai K, Kodama T, Ichimaru Y, Yana T, Hirata K. Phase II study of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer. *J Thorac Oncol* 2009; **4**: 371-375 [PMID: 19155998 DOI: 10.1097/JTO.0b013e31819846e4]

20 **Calvert AH**, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. *J Clin Oncol* 1989; **7**: 1748-1756 [PMID: 2681557]

21 **Jellifie RW**, Jelliffe SM. A computer program for estimation of creatine clearance from unstable serum creatine levels, age, sex and weight. *Math Biosci* 1972; **14**: 17–24 doi: 10.1016/0025-5564(72)90003-X

22 **Kasahara K**, Kimura H, Shibata K, Araya T, Sone T, Oribe Y, Furusho S, Kita T, Shirasaki H, Oribe Y, Yoshimi Y, Ueda A, Tachibana H, Shintani H, Mizuguchi M, Nishi K, Fujimura M, Nakao S. A phase II study of combination chemotherapy with docetaxel and carboplatin for patients with advanced or metastatic non-small cell lung cancer. *Anticancer Res* 2006; **26**: 3723-3728 [PMID: 17094391]

23 **Simon R**. Optimal two-stage designs for phase II clinical trials. *Control Clin Trials* 1989; **10**: 1-10 [PMID: 2702835 DOI: 10.1016/0197-2456(89)90015-9]

24 **Uramoto H**, Uchiyama A, Inoue M, Iwata T, Ebi N, [Hanagiri T](http://www.ncbi.nlm.nih.gov/pubmed?term=Hanagiri%20T%5BAuthor%5D&cauthor=true&cauthor_uid=20683052), Tanaka F. A Phase II trial of adjuvant chemotherapy with tri-weekly carboplatin plus docetaxel in patients with completely resected non-small cell lung cancer: interim analysis. 5th Asia Pacific Lung Cancer Conference 2012; 072.

25 **Epelbaum R**, Faraggi D, Ben-Arie Y, Ben-Shahar M, Haim N, Ron Y, Robinson E, Cohen Y. Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables. *Cancer* 1990; **66**: 1124-1129 [PMID: 2205353 DOI: 3.0.CO; 2-T']

26 **Bonadonna G**, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. *N Engl J Med* 1995; **332**: 901-906 [PMID: 7877646 DOI: 10.1056/NEJM199504063321401]

27 **Neymark N**, Crott R. Impact of emesis on clinical and economic outcomes of cancer therapy with highly emetogenic chemotherapy regimens: a retrospective analysis of three clinical trials. *Support Care Cancer* 2005; **13**: 812-818 [PMID: 15834590 DOI: 10.1007/s00520-005-0803-x]

28 **Felip E**, Rosell R, Maestre JA, Rodríguez-Paniagua JM, Morán T, Astudillo J, Alonso G, Borro JM, González-Larriba JL, Torres A, Camps C, Guijarro R, Isla D, Aguiló R, Alberola V, Padilla J, Sánchez-Palencia A, Sánchez JJ, Hermosilla E, Massuti B. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. *J Clin Oncol* 2010; **28**: 3138-3145 [PMID: 20516435 DOI: 10.1200/JCO.2009.27.6204]

29 **Kato H**, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N, Ohta M. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. *N Engl J Med* 2004; **350**: 1713-1721 [PMID: 15102997 DOI: 10.1056/NEJMoa032792]

30 **Arriagada R**, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. *N Engl J Med* 2004; **350**: 351-360 [PMID: 14736927 DOI: 10.1056/NEJMoa031644]

31 **Strauss GM**, Herndon JE, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, Gillenwater HH, Watson DM, Sugarbaker DJ, Schilsky RL, Vokes EE, Green MR. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. *J Clin Oncol* 2008; **26**: 5043-5051 [PMID: 18809614 DOI: 10.1200/JCO.2008.16.4855]

32 **Kubota K**, Kunitoh H, Seto T, Shimada N, Tsuboi M, Okamoto H, Masuda N, Maruyama R, Shibuya M, Watanabe K. A randomized phase II trial of adjuvant chemotherapy with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: Safety and feasibility data from trial TORG 0503. *J Clin Oncol* 2009; **27**: 7561.

33 **Yang XN**, Cheng G, Ben XS, Luo HH, Wang CL, Zhong W, Ge D, Qiao GB, Wang Z, Shentu Y, Yang J, Yan HH, Wu YL. Survival study of neoadjuvant versus adjuvant chemotherapy with docetaxel combined carboplatin in resectable stage IB to IIIA non-small lung cancer. *J Clin Oncol* 2013; **31**, 7537.

34 **Maruyama R**, Yoshino I, Tokunaga S, Ohta M, Kato M, Yoshimine H, Yamazaki K, Nakanishi Y, Ichinose Y. Feasibility trial of adjuvant chemotherapy with paclitaxel and carboplatin after surgical resection in Japanese patients with non-small cell lung cancer: report of the Lung Oncology Group in Kyushu (LOGIK) protocol 0501. *Gen Thorac Cardiovasc Surg* 2008; **56**: 68-73 [PMID: 18297461 DOI: 10.1007/s11748-007-0188-5]

35 **Gandara DR**, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, Teramukai S, Ohe Y, Kubota K, Williamson SK, Gautschi O, Lenz HJ, McLeod HL, Lara PN, Coltman CA, Fukuoka M, Saijo N, Fukushima M, Mack PC. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. *J Clin Oncol* 2009; **27**: 3540-3546 [PMID: 19470925 DOI: 10.1200/JCO.2008.20.8793]

36 **Sun HB**, Wang SY, Ou W, Zhang BB, Yang H, Fang Q. The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected locally advanced non-small cell lung cancer. *Lung Cancer* 2010; **68**: 403-408 [PMID: 19913325 DOI: 10.1016/j.lungcan.2009.10.002]

37 **Sawabata N**, Miyaoka E, Asamura H, Nakanishi Y, Eguchi K, Mori M, Nomori H, Fujii Y, Okumura M, Yokoi K. Japanese lung cancer registry study of 11,663 surgical cases in 2004: demographic and prognosis changes over decade. *J Thorac Oncol* 2011; **6**: 1229-1235 [PMID: 21610521 DOI: 10.1097/JTO.0b013e318219aae2]

**P-Reviewers:** Altug S, Huang CJ, Garfield D, Freixinet JL **S-Editor:** Wen LL  **L-Editor:**  **E-Editor:**

##### **Figure 1 Recurrence-free survival.** A: The 2-year recurrence-free survival (RFS) rate was 69.8%. B: The RFS curves stratified by pathological stage. IB:Heaviest line; II: Second heaviest line; IIIA: Thin line.

**Figure 2 Overall survival.** A: The 2-year overall survival (OS) rate was 88.3%; B: The OS curves stratified by pathological stage. IB: Heaviest line; II: Second heaviest line; IIIA: Thin line.

**Table 1 Patient characteristics**

|  |  |
| --- | --- |
| **Characteristic** | ***n* = 61** |
| Gender |  |
|  Male | 43 |
|  Female | 18 |
| Age, yr | 66 (42-79) |
| Histology |  |
|  Adenocarcinoma | 45 |
|  Squamous cell carcinoma | 13 |
|  Pleomorphic carcinoma | 2 |
|  Giant cell carcinoma | 1 |
| Lesion site |  |
|  Right | 42 |
|  Left | 19 |
| Lesion location |  |
|  Upper | 38 |
|  Middle | 1 |
|  Lower  | 22 |
| Pathological stage (7th) |  |
|  IB | 17 |
|  IIA | 14 |
|  IIB | 8 |
|  IIIA | 22 |
| Surgical procedure |  |
|  Sublobar resection | 2 |
|  Lobectomy | 58 |
|  Pneumonectomy | 1 |

**Table 2 Drug delivery *n* (%)**

|  |  |
| --- | --- |
| **Number of cycles delivered** |  |
|  1 | 61 (100) |
|  2  | 58 (95) |
|  3 | 51 (84) |
|  Total | 170 |
|  Median | 3 |
| Number of patients who required dose reduction of  CBDCA | 43 (70) |
|  DTX | 43 (70) |
| Mean dose intensity (% planned) |  |
|  CBDCA | 4.3 AUC (86.7) |
|  DTX | 51.8 mg/m2 (86.3) |
| Median dose intensity (% planned) |  |
|  CBDCA | 4.3 AUC (86.7) |
|  DTX | 53.3 mg/m2 (88.8) |

**Table 3 Worst adverse events that occurred in the present study *n* (%)**

|  |  |  |
| --- | --- | --- |
| **Toxicity** | **Grade 3**  | **Grade 4**  |
| Hematological events |  |  |
|  Neutropenia | 15 (25) | 40 (66) |
|  Febrile neutropenia | 4 (7) | 0 (0) |
| Non-hematological events |  |  |
|  Anorexia | 41 (7) | 0 (0) |
|  Nausea | 21 (3) | 0 (0) |
|  General fatigue | 2 (3) | 0 (0) |
|  GI disorder2 |  | 1 (2) |
|  Diarrhea | 1 (2) |  |

1Two patients had both anorexia and nausea; 2Intra-abdominal abscess from ileocecal diverticulitis. GI: Gastrointestinal.

**Table 4 The pathological stages and types of recurrence *n* (%)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Pathological stage (7th)** | **No. of cases** | **Local** | **Systemic** |
| IB | 17 | 0 | 1 |
| IIA | 14 | 2 | 2 |
| IIB | 8 | 0 | 3 |
| IIIA | 22 | 7 | 10 |
| Total | 61 | 9 (15) | 16 (26) |

Five patients had both local and systemic recurrent tumors